About artelo biosciences inc - ARTL
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.
ARTL At a Glance
Artelo Biosciences, Inc.
505 Lomas Santa Fe
Solana Beach, California 92075
| Phone | 1-858-925-7049 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -12,879,000.00 | |
| Sector | Health Technology | Employees | 7 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ARTL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.117 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.508 |
ARTL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,839,857.143 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ARTL Liquidity
| Current Ratio | 0.172 |
| Quick Ratio | 0.172 |
| Cash Ratio | 0.148 |
ARTL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -343.486 |
| Return on Equity | -1,625.11 |
| Return on Total Capital | 2,168.182 |
| Return on Invested Capital | -1,530.481 |
ARTL Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -114.141 |
| Total Debt to Total Assets | 24.206 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -4.882 |